Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
SP2509
CHF 0.00
In stock
SYN-1212-M0011 mgCHF 170.00
SYN-1212-M0055 mgCHF 355.00
SYN-1212-M01010 mgCHF 553.00
SYN-1212-M100100 mgINQ
SYN-1212-M05050 mgINQ
| Product Details | |
|---|---|
| Synonyms | SP-2509 |
| Product Type | Chemical |
| Properties | |
| Formula | C19H20ClN3O5S |
| MW | 437.9 |
| CAS | 1423715-09-6 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: LSD1 | Kinase Group: N/A | Substrate: N/A Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | NKUDGJUBIVEDTF-FYJGNVAPSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1 inhibitor with an IC(50) of 10nM. SP-2528 demonstrates a high specificity for LSD1, with no effect on MAOi.
Product References
- High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors: V. Sorna, et al.; J. Med. Chem. 56 9496 (2013)
- Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells: W. Fiskus, et al.; Leukemia 28, 2155 (2014)
Related Products
